The Ledger

1.32 billion dollars: that is what Jazz Pharmaceuticals is paying to buy a rare epilepsy drug that has never treated a single paying patient, the company’s boldest bet yet on a genetic disorder no approved drug touches. Jazz Pharmaceuticals announced August 10, 2026 that it will acquire Actio Biosciences, a clinical stage biotechnology company, for 820 million dollars upfront in cash plus up to 500 million dollars in contingent milestone payments tied to regulatory approval and sales targets. The deal centers on ABS-1230, a first-in-class oral inhibitor of the KCNT1 ion channel designed to treat KCNT1-related epilepsy, a rare genetic developmental and epileptic encephalopathy that affects roughly 2,500 patients in the United States and has no FDA-approved treatment; the drug has shown early seizure reductions in clinical trials and holds FDA Fast Track and Orphan Drug designations. As part of the deal, Actio will spin out a separate, privately held company retaining other assets and staff, while ABS-1230 transfers to Jazz, which expects to close the acquisition in the fourth quarter of 2026, funded from cash on hand and existing financing facilities. Confidence: High. The deal terms, asset details and timeline come directly from Jazz’s own press release. Sources: Jazz Pharmaceuticals to Acquire Actio Biosciences, Expanding Rare Epilepsy Portfolio, Jazz Pharmaceuticals investor relations, Jazz Pharmaceuticals to Acquire Actio Biosciences, Expanding Rare Epilepsy Portfolio, PR Newswire.

5.7 billion dollars: that is what KKR is paying to take a medical device manufacturer private, the private equity firm’s biggest healthcare bet since it bought Envision Healthcare for 9.9 billion dollars in 2018. Integer Holdings, a contract manufacturer that designs and builds components and finished devices for cardiovascular, neuromodulation, vascular, orthopedic and advanced surgical device makers, agreed August 3, 2026 to be acquired by KKR in an all-cash deal valued at approximately 5.7 billion dollars; Integer shareholders will receive 127 dollars per share, a premium to the stock’s last close before the announcement. KKR, which managed 796 billion dollars in assets as of the end of its second quarter, will finance the purchase with equity from its funds plus committed debt financing; the deal is expected to close by the end of 2026, subject to shareholder and regulatory approval. Confidence: High. The deal terms come directly from Integer’s own investor relations release. Source: Integer to Be Acquired by KKR in Transaction Valued at Approximately $5.7 Billion, Integer Holdings investor relations.

800 million dollars: that is the top-end price tag on a private equity firm’s bet on the fragile supply chain that keeps nuclear medicine scans and emerging radioactive cancer therapies stocked with isotopes. FRONTIER SCAN. BWX Technologies agreed August 3, 2026 to sell its medical business, which includes BWXT Medical and Kinectrics’ stable medical isotopes unit, to private equity firm Nordic Capital in a transaction valued at up to 800 million dollars; BWXT will retain a minority stake and keep supplying specialized isotope and radiochemical expertise to the divested business. BWXT first acquired the medical isotopes operations in 2018 and says it has roughly tripled the business’s revenue since, expanding into novel therapeutic isotopes used in emerging radiopharmaceutical cancer treatments; Nordic Capital, which manages roughly 39 billion euros in assets, plans to use its ownership to scale the radiopharmaceutical business further, while BWXT redirects capital toward its nuclear national security and commercial nuclear power markets. The deal is expected to close by the end of 2026, subject to regulatory approval. Confidence: High. The transaction terms come directly from BWXT’s own investor relations release. Source: BWXT Selling Medical Business to Nordic Capital in Transaction Valued at up to $800 Million, BWX Technologies investor relations.

2.2 billion dollars: that is the annual revenue projected for a new central nervous system drug company being created by an all-stock merger of equals, built around an opioid addiction treatment nearing 1 billion dollars in yearly sales. Supernus Pharmaceuticals and Indivior announced August 3, 2026 a definitive agreement to combine in a tax-free, all-stock merger of equals, with Supernus shareholders receiving 1.5401 Indivior shares for each share held; post-close, Indivior shareholders will own 56.5 percent of the combined company and Supernus shareholders 43.5 percent. Before closing, Indivior will pay its pre-closing stockholders a 1 billion dollar special cash dividend, funded partly by an assumed additional 650 million dollars in debt. The combined company, to be renamed Supernus, Inc. and trade on the Nasdaq under the ticker SUPN, projects roughly 2.2 billion dollars in annual revenue, 888 million dollars in pro forma adjusted EBITDA and 125 million dollars in annual cost synergies, built around 11 marketed central nervous system medicines led by Indivior’s Sublocade, an extended-release buprenorphine injection for opioid use disorder that generated nearly 1 billion dollars in sales over the 12 months ended June 30, 2026. The merger is targeted to close in the fourth quarter of 2026, pending shareholder and regulatory approval. Confidence: High. The deal terms and revenue figures come directly from the companies’ own joint press release. Source: Supernus Pharmaceuticals and Indivior Pharmaceuticals to Merge, Creating a Diversified CNS Biopharmaceutical Leader with Significant Scale, Indivior.

147 million dollars: that is what a healthcare analytics company collected by selling off its revenue cycle software business, money it used to wipe out 160 million dollars in debt in a single stroke. Health Catalyst completed the sale of Vitalware, its revenue cycle workflow optimization and analytics software unit, to Med-Metrix, a technology-enabled revenue cycle management company, for 147 million dollars in cash; Vitalware generated approximately 37 million dollars in fiscal year 2025 revenue. Health Catalyst combined the proceeds with cash on hand to fully repay and retire its credit facility, retiring approximately 160 million dollars in outstanding debt and eliminating about 19 million dollars in annual GAAP interest expense, while the company says the divestiture sharpens its focus on artificial intelligence and analytics for health systems. Confidence: High. The transaction terms and use of proceeds come directly from Health Catalyst’s own investor relations release. Source: Health Catalyst to Divest Vitalware for $147 Million, Accelerating Strategic Transformation, Health Catalyst investor relations.

THE DEAL SHEET

Target	Acquirer/Investor	Vertical	Value	Source
Actio Biosciences	Jazz Pharmaceuticals	Rare disease pharma, epilepsy	$820 million upfront plus up to $500 million in milestones; announced August 10, 2026, expected to close Q4 2026	Jazz Pharmaceuticals to Acquire Actio Biosciences, PR Newswire
Integer Holdings	KKR	Medtech contract manufacturing (CDMO)	$5.7 billion all-cash take-private, $127 per share; announced August 3, 2026, expected to close by year end	Integer to Be Acquired by KKR, Integer Holdings investor relations
BWXT Medical and Kinectrics’ medical isotopes business	Nordic Capital (BWX Technologies retains minority stake)	Nuclear medicine, radioisotope supply chain	Up to $800 million; announced August 3, 2026, expected to close by year end	BWXT Selling Medical Business to Nordic Capital, BWX Technologies investor relations
Supernus Pharmaceuticals	Indivior (merger of equals)	Central nervous system pharma	All-stock; combined entity projects $2.2 billion annual revenue; announced August 3, 2026, targeted to close Q4 2026	Supernus Pharmaceuticals and Indivior Pharmaceuticals to Merge, Indivior
Alkeus Pharmaceuticals	Tarsus Pharmaceuticals	Rare disease pharma, ophthalmology	Up to $800 million ($270 million cash plus $180 million stock upfront, plus milestones); agreement dated July 31, 2026, expected to close in 2026	Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals, GlobeNewswire
Teleflex Medical OEM and Development Services business	Montagu and Kohlberg (rebranded Ingenyx)	Medtech contract manufacturing (OEM)	$1.5 billion cash; sale completed August 3, 2026	Teleflex Completes Strategic Divestiture of OEM Business for $1.5 Billion, Teleflex investor relations
Vitalware	Med-Metrix (divested by Health Catalyst)	Healthcare revenue cycle management software	$147 million cash; divestiture completed, confirmed early August 2026	Health Catalyst to Divest Vitalware for $147 Million, Health Catalyst investor relations

This run’s scan of PE Hub, Axios Pro Rata, FTC and DOJ merger actions and state transaction-review dockets over the last 24 to 48 hours turned up no new FTC or DOJ healthcare antitrust actions beyond the seven transactions above.